Insulin Glargine U300 vs Insulin Degludec U100 in Impact on the Glycaemic and Cardiovascular Factors
Diabetes Mellitus, Type 2

About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring Diabetes mellitus type 2, degludec, glargine U300, glucose variability, lipids, arterial stiffness, oxidative stress
Eligibility Criteria
Inclusion Criteria:
- a history of DMT2 for at least 1 year
- aged between 18 and 65 years (women obligatory postmenopausal)
- uncontrolled glycaemia on two or more oral antidiabetic drugs
- no prior use of insulin
- HbA1c ≥7.5%
- receiving statins (if not on statins, they were put on it)
- not on antiaggregant therapy (if on antiaggregants, they were temporarily excluded from therapy)
Exclusion criteria:
- the presence of malignant disease
- chronic liver disease
- renal impairment with creatinine clearance < 60 ml/s
- severe cardiovascular disease or history of cardiovascular incidents (stroke, myocardial infarction, peripheral amputation)
- rheumatic and autoimmune diseases and the usage of glitazones or anticoagulant therapy
Sites / Locations
- Klinički bolnički Centar Split
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
degludec arm
glargine arm
25 patients were discontinued their previous therapy and given metformin alone (2 g/day) for seven days. After seven days they were randomized to first receive IDeg-100 In phase one they received IDeg-100 and metformin for 12 weeks. Phase one was followed by a second wash-up period in which patients received metformin alone again for seven days. In phase two, which also lasted for 12 weeks, patients were switched from IDeg-100 to IGlar-300 (and metformin was continued). The initial dose of both insulins was 0.2 IU/kg.
25 patients were discontinued their previous therapy and given metformin alone (2 g/day) for seven days. After seven days they were randomized to first receive IGlar-300 In phase one they received IGlar-300 and metformin for 12 weeks. Phase one was followed by a second wash-up period in which patients received metformin alone again for seven days. In phase two, which also lasted for 12 weeks, patients were switched from IGlar-300 to IDeg-100 (and metformin was continued). The initial dose of both insulins was 0.2 IU/kg.